A confirmed case of xylazine-induced skin ulcers in a person who injects drugs in Miami, Florida, USA
Background Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the illicit drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who use drugs (PWUD). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida. Case presentation A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at a Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits were informed by best clinical judgement due to lack of formal guidelines at the time. Wound outcomes are unknown as the patient has not returned to clinic. Conclusions Many PWUD at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system due to stigma. There is an urgent need for access to XTS for PWUD and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Harm reduction journal - 21(2024), 1 vom: 15. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Warp, Peyton V. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Harm reduction |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12954-024-00978-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055172571 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055172571 | ||
| 003 | DE-627 | ||
| 005 | 20240316064743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240316s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12954-024-00978-z |2 doi | |
| 035 | |a (DE-627)SPR055172571 | ||
| 035 | |a (SPR)s12954-024-00978-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Warp, Peyton V. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A confirmed case of xylazine-induced skin ulcers in a person who injects drugs in Miami, Florida, USA |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the illicit drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who use drugs (PWUD). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida. Case presentation A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at a Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits were informed by best clinical judgement due to lack of formal guidelines at the time. Wound outcomes are unknown as the patient has not returned to clinic. Conclusions Many PWUD at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system due to stigma. There is an urgent need for access to XTS for PWUD and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics. | ||
| 650 | 4 | |a Xylazine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Opioid use disorder |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Injection drug use |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Wounds |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Xylazine test strip |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Harm reduction |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hauschild, Maia |4 aut | |
| 700 | 1 | |a Serota, David P. |4 aut | |
| 700 | 1 | |a Ciraldo, Katrina |4 aut | |
| 700 | 1 | |a Cruz, Irasema |4 aut | |
| 700 | 1 | |a Bartholomew, Tyler S. |4 aut | |
| 700 | 1 | |a Tookes, Hansel E. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Harm reduction journal |d BioMed Central, 2004 |g 21(2024), 1 vom: 15. März |w (DE-627)SPR028770668 |w (DE-600)2146691-9 |x 1477-7517 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:1 |g day:15 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12954-024-00978-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 1 |b 15 |c 03 | ||